HDT Bio, Gennova Biopharmaceuticals Announce First Healthy Volunteers Dosed in Phase I/II Trials Of Unique COVID-19 RNA Vaccine in India

HDT Bio’s RNA-based vaccine offers simpler manufacturing, easier deployment, and requires vastly lower dosing than current COVID-19 vaccines SEATTLE--(BUSINESS WIRE)--HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases, ...

Full "IntellAsia: Resources" article